Recombinant MS4A1 (Rituximab Biosimilar) anticorps

N° du produit ABIN7487776

Détail du produit anti-MS4A1 (Rituximab Biosimilar) anticorps

Antigène: MS4A1 (Rituximab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Mammalian Cells

Expression System: Mammalian cells

Clonalité: Monoclonal

Conjugué: Cet anticorp MS4A1 (Rituximab Biosimilar) est non-conjugé

Application: ELISA

Fonction: Rituximab Biosimilar - Anti-MS4A1 mAb

Attributs du produit: Antibody Type: IgG1

Purification: Recombinant antibody expressed in mammalien cells and purified.

Classe de qualité: Research Grade

Isotype: IgG1

Information d'application

Restrictions: For Research Use only

Stockage

Buffer: PBS pH 7.5

Stock: 4 °C,-20 °C

Stockage commentaire: 4°C for short term, -20°C for long term

Détails sur MS4A1 (Rituximab Biosimilar)

Antigène: MS4A1 (Rituximab Biosimilar)

Abstract: MS4A1 (Rituximab Biosimilar) Produits

Synonymes: anticorps B1, anticorps Bp35, anticorps CD20, anticorps CVID5, anticorps LEU-16, anticorps MS4A2, anticorps S7, anticorps membrane spanning 4-domains A1, anticorps MS4A1

Classe de substances: Biosimilar

Sujet: Rituximab
Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. When it binds to this protein it triggers cell death. Rituximab is a medication used to treat certain autoimmune diseases and types of cancer. It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, pemphigus vulgaris, myasthenia gravis and Epstein–Barr virus-positive mucocutaneous ulcers.